-
234Wire StoriesArizona Sonoran Appoints Hannam & Partners as Project Finance Advisor for the Cactus Project
CASA GRANDE, Ariz. & TORONTO–(BUSINESS WIRE)–$ASCU #Arizona—Arizona Sonoran Copper Company Inc. (TSX:ASCU | OTCQX:ASCUF) (“ASCU” or the “Company”) is pleased to announce...
-
261Wire StoriesKKR Provides $600 Million Financing to Indian Conglomerate Manipal Group
Transaction marks KKR’s latest and largest credit investment in India MUMBAI, India–(BUSINESS WIRE)–KKR, a leading global investment firm, and Manipal Education and...
-
223NewsKenanga Investors Launches New Global Real Asset Fund
The Kenanga Alternative Series: Global Real Assets Fund offers investors exposure primarily to global real estate, precious metals, and commodities by employing...
-
257Wire StoriesMarkHerz Signs MOU with TUM Hospital for Joint Development of Cardiovascular and Diabetes-Targeted AAV Gene Therapies
Paving the Way for European Clinical Entry and Global Technology Transfer A Milestone Partnership Highlighting Korea’s Expanding Influence in Global Biotech Innovation...
-
234Wire StoriesImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
SEOUL, South Korea–(BUSINESS WIRE)–ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration...
-
302Wire StoriesSoftware Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
MARLBOROUGH, Mass.–(BUSINESS WIRE)–#AI—SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software...
-
325Wire StoriesZai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
– Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose...
-
304Wire StoriesJames Hardie Industries plc Announces Proposed Private Offering of Senior Secured Notes
SYDNEY–(BUSINESS WIRE)–James Hardie Industries plc (ASX: JHX) (“James Hardie” or the “Company”) announced today that its wholly-owned subsidiary, JH North America Holdings...
-
250Wire StoriesAEye’s Apollo Lidar Sensor Wins Prestigious AIIA Intelligent Perception Industry Leadership Award
PLEASANTON, Calif.–(BUSINESS WIRE)–AEye, Inc. (Nasdaq: LIDR), a global leader in adaptive, high-performance lidar solutions, announced today that its flagship 1550 nm lidar...
-
264Wire StoriesENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a...
